A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

Phase 2 Completed 21 enrolled Spanish Group for Research in Neuroendocrine Tumors

NaSingle-groupOpen-labelTreatment

Summary

A phase II trial to assess the activity and safety of PD0332991 in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET) with overexpression of cell cycle markers (Cdk4 and/or phospho-Rb1 and/or cyclin D1)

Timeline

Start: 2015-05
Primary completion: 2017-07
Completion: 2018-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Palbociclib	Small molecule	—	—

A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

Summary

Timeline

Drugs

Indications